(¿Â¶óÀÎ) 2021 Á¦ 62Â÷ ´ëÇÑÇ÷¾×ÇÐȸ Ãß°èÇмú´ëȸ : 2021-11-05±³À°ÀÏÀÚ : 2021-11-05
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2021 Á¦ 62Â÷ ´ëÇÑÇ÷¾×ÇÐȸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ :
hematology@kams.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í Á¤È¸¿ø 30,000¿ø, °£È£»ç/Àü°øÀÇ/¿¬±¸¿ø 20,000¿ø, ºñȸ¿ø 50,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-05 A 10:00~10:30 NGS¸¦ ÀÌ¿ëÇÑ MRD Æò°¡ÀÇ Ç¥ÁØÈ ÀÌÁö¼ö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-05 A 10:30~11:00 ¼Ò¾Æ AML¿¡¼ÀÇ ¸é¿ªÄ¡·á °¼ºÇÑ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 11-05 A 11:00~11:30 °í·É AML ȯÀÚ¸¦ À§ÇÑ º¸´Ù Àû ÀýÇÑ ¿¹ÈÄ Æò°¡ ¹æ¹ý À±¼ºÀ±(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 11-05 A 11:30~12:00 MDS¿¡¼ HMA Ä¡·á ÀúÇ×ÀÇ ±âÀü, ¿¹Ãø ¹× ´ëÃ¥ ¹Ú¿ë(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-05 A 13:00~13:30 BCR/ABL1 gene mutation detection using NGS ½Å»õ¾Ï(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 11-05 A 13:30~14:00 Survey on controversial issues and clinical practice in CML from the Korean CML WP ÀÌÁ¤¿Á(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11-05 A 14:00~14:30 Atypical CML À̼ºÀº(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 11-05 A 14:30~15:00 MPN with eosinophilia Á¤¼ºÈÆ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 11-05 C 15:30~16:00 Updates in risk assessment for myeloma °°¡¿ø(°í·ÁÀÇ´ë)
±³À°½Ã°£ 11-05 C 16:00~16:30 Triplet and quadruplet therapies for newly diagnosed multiple myelom ±è¹Î°æ(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 11-05 C 16:30~17:00 Key considerations for relapsed myeloma ¹®ÁØÈ£(°æºÏÀÇ´ë)
±³À°½Ã°£ 11-05 C 17:00~17:30 How to treat high-risk multiple myeloma °í¿µÀÏ(¼¿ïÀÇ´ë)